Human Herpesvirus 8 (HHV-8) poses a significant risk in solid organ transplant recipients (SOTRs). HHV-8 is implicated in both neoplastic and non-neoplastic conditions. This study investigates immune dysregulation in HHV-8-infected SOTRs by analysing cytokine profiles and virus-specific T cell responses across different clinical manifestations. Our findings reveal a progressive decline in HHV-8-specific T cell responses correlating with disease severity, alongside a distinct cytokine signature. KICS patients exhibit heightened inflammation with elevated IL-6, IL-10, IFNα, TNFα, IL-1β, IL-17 A, IDO, sCD14, and immune exhaustion markers (PD-1, LAG-3), whereas KS is associated with angiogenic and macrophage activation factors (HGF, CD163). Given these insights, monitoring HHV-8 DNAemia, inflammatory cytokines, and T cell functionality is crucial for early detection and risk stratification. This study underscores the importance of immune monitoring in transplant recipients, paving the way for targeted interventions to mitigate HHV-8-associated complications.
{"title":"Immune profiling in solid organ transplant recipients with HHV-8 infection: Identification of immunological biomarkers for KICS and Kaposi's sarcoma","authors":"Rosalia Busà , Francesca Timoneri , Monica Miele , Mariangela Di Bella , Andrea Cona , Salvatore Castelbuono , Mattia Emanuela Ligotti , Alessia Gallo , Francesca Pecoraro , Giuseppe Randazzo , Caterina Amato , Clara Pipia , Giandomenico Amico , Valentina Agnese , Pier Giulio Conaldi , Mario Luppi , Alessandra Mularoni , Matteo Bulati","doi":"10.1016/j.clim.2025.110562","DOIUrl":"10.1016/j.clim.2025.110562","url":null,"abstract":"<div><div>Human Herpesvirus 8 (HHV-8) poses a significant risk in solid organ transplant recipients (SOTRs). HHV-8 is implicated in both neoplastic and non-neoplastic conditions. This study investigates immune dysregulation in HHV-8-infected SOTRs by analysing cytokine profiles and virus-specific T cell responses across different clinical manifestations. Our findings reveal a progressive decline in HHV-8-specific T cell responses correlating with disease severity, alongside a distinct cytokine signature. KICS patients exhibit heightened inflammation with elevated IL-6, IL-10, IFNα, TNFα, IL-1β, IL-17 A, IDO, sCD14, and immune exhaustion markers (PD-1, LAG-3), whereas KS is associated with angiogenic and macrophage activation factors (HGF, CD163). Given these insights, monitoring HHV-8 DNAemia, inflammatory cytokines, and T cell functionality is crucial for early detection and risk stratification. This study underscores the importance of immune monitoring in transplant recipients, paving the way for targeted interventions to mitigate HHV-8-associated complications.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110562"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144604458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-07DOI: 10.1016/j.clim.2025.110558
Xukang Gao , Min Xu , Hao Xiao , Zeping Han , Zhutao Wang , Guoqiang Sun , Dai Zhang , Qiu Shuangjian , Ning Ren , Chenhao Zhou , Yong Yi
Neutrophils, constituting 50–70 % of circulating leukocytes, serve as first responders in innate immunity. In recent years, as research into the tumor immune microenvironment has intensified, the role of neutrophils in tumor has gained increasing attention. Studies have shown that neutrophils are involved in tumor growth, metastasis, angiogenesis, and immune regulation. However, because tumor-associated neutrophils (TANs) often exhibit dual-edged effects and significant heterogeneity, it remains challenging to determine whether they act as allies or adversaries. This review systematically summarizes the classification and functions of neutrophils in tumor. Additionally, the current challenges in tumor-associated neutrophils are discussed, aiming to provide new insights for the development of neutrophil-related immunotherapies.
{"title":"Tumor-associated neutrophils: a complex role in cancer","authors":"Xukang Gao , Min Xu , Hao Xiao , Zeping Han , Zhutao Wang , Guoqiang Sun , Dai Zhang , Qiu Shuangjian , Ning Ren , Chenhao Zhou , Yong Yi","doi":"10.1016/j.clim.2025.110558","DOIUrl":"10.1016/j.clim.2025.110558","url":null,"abstract":"<div><div>Neutrophils, constituting 50–70 % of circulating leukocytes, serve as first responders in innate immunity. In recent years, as research into the tumor immune microenvironment has intensified, the role of neutrophils in tumor has gained increasing attention. Studies have shown that neutrophils are involved in tumor growth, metastasis, angiogenesis, and immune regulation. However, because tumor-associated neutrophils (TANs) often exhibit dual-edged effects and significant heterogeneity, it remains challenging to determine whether they act as allies or adversaries. This review systematically summarizes the classification and functions of neutrophils in tumor. Additionally, the current challenges in tumor-associated neutrophils are discussed, aiming to provide new insights for the development of neutrophil-related immunotherapies.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110558"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-11DOI: 10.1016/j.clim.2025.110563
Fatima Zaman , Xianming Zhu , Joanne H. Hunt , Gracie Rozek , Yolanda Eby , Sarah Hussain , Niraj M. Desai , Sander Florman , Meenakshi M. Rana , Rachel Friedman-Moraco , Marcus R. Pereira , Shikha Mehta , Peter Stock , Alexander Gilbert , Jonathan Hand , Michele I. Morris , Valentina Stosor , Sapna A. Mehta , Catherine B. Small , Joanna Schaenman , Aaron A.R. Tobian
Kidney transplantation from donors with HIV has recently become standard clinical practice, but the plasma inflammatory profile is not well characterized. Thirty-two cytokines and chemokines were evaluated among donors with HIV (n = 63) and without HIV (n = 41). Wilcoxon rank sum test was used to compare cytokines between groups. Donors with and without HIV were generally similar in terms of characteristics, except those with HIV had a non-significantly lower kidney donor profile index, reflecting better graft survival, creatinine, and body mass index. Most cytokine and chemokine levels were similar between groups. However, median IL-8 levels were higher (p < 0.0015) in donors without HIV (32.6 pg/mL, IQR = 13.8–394.9) compared to donors with HIV (15.1 pg/mL, IQR = 8.4–35.5). There were no significant correlations between cytokine and chemokine concentrations and CD4 counts or HIV viral load. In summary, inflammatory profiles were similar or lower among donors with HIV compared to donors without HIV supporting the safety of this emerging kidney transplantation practice.
{"title":"Inflammation among kidney transplant donors with and without HIV: Multicenter HOPE in Action Consortium","authors":"Fatima Zaman , Xianming Zhu , Joanne H. Hunt , Gracie Rozek , Yolanda Eby , Sarah Hussain , Niraj M. Desai , Sander Florman , Meenakshi M. Rana , Rachel Friedman-Moraco , Marcus R. Pereira , Shikha Mehta , Peter Stock , Alexander Gilbert , Jonathan Hand , Michele I. Morris , Valentina Stosor , Sapna A. Mehta , Catherine B. Small , Joanna Schaenman , Aaron A.R. Tobian","doi":"10.1016/j.clim.2025.110563","DOIUrl":"10.1016/j.clim.2025.110563","url":null,"abstract":"<div><div>Kidney transplantation from donors with HIV has recently become standard clinical practice, but the plasma inflammatory profile is not well characterized. Thirty-two cytokines and chemokines were evaluated among donors with HIV (<em>n</em> = 63) and without HIV (<em>n</em> = 41). Wilcoxon rank sum test was used to compare cytokines between groups. Donors with and without HIV were generally similar in terms of characteristics, except those with HIV had a non-significantly lower kidney donor profile index, reflecting better graft survival, creatinine, and body mass index. Most cytokine and chemokine levels were similar between groups. However, median IL-8 levels were higher (<em>p</em> < 0.0015) in donors without HIV (32.6 pg/mL, IQR = 13.8–394.9) compared to donors with HIV (15.1 pg/mL, IQR = 8.4–35.5). There were no significant correlations between cytokine and chemokine concentrations and CD4 counts or HIV viral load. In summary, inflammatory profiles were similar or lower among donors with HIV compared to donors without HIV supporting the safety of this emerging kidney transplantation practice.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110563"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-09DOI: 10.1016/j.clim.2025.110557
Katarina Mirjačić Martinović , Ana Vuletić , Nevena Tišma Miletić , Milica Nedeljković , Suzana Matković , Vladimir Jurišić
Therapeutical blockade of programmed cell death protein 1 (PD-1) axis may enhance anti-tumor immunity and especially natural killer (NK) cells activity. In 32 BRAF wild type (wt) metastatic melanoma (MM) patients before and after every 12 weeks of therapy with PD-1 inhibitor, Pembrolizumab, we analyzed the percentage of T cell subsets, NK cells and CD14+HLA-DR− monocytes, the expression of CD107a degranulation marker, activating NKG2D, NKp46, DNAM-1 and inhibitory CD158a receptors on NK cells by Flow cytometry, until one year or disease progression (DP). The patients with disease control (non-DP patients) had significant increase in lymphocyte count, percentage of NK cells, increased expression of CD107a, NKG2D, NKp46, but decreased CD158a on NK cells during Pembrolizumab therapy compared to pretherapy values. Patients with DP had increased neutrophil number, increased percentage of immunosuppressive CD14+HLA-DR− monocytes, as well as increased CD158a expression on NK cells. In MM patients with disease control, contrary to DP patients blocking of PD-1 inhibitory molecule may increase NK cell cytotoxicity through enhancement of NK cell degranulation and activating receptor expression. Therefore, our findings show that NK cells and their receptors in MM patients may be potential biomarkers of response to Pembrolizumab.
{"title":"Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients","authors":"Katarina Mirjačić Martinović , Ana Vuletić , Nevena Tišma Miletić , Milica Nedeljković , Suzana Matković , Vladimir Jurišić","doi":"10.1016/j.clim.2025.110557","DOIUrl":"10.1016/j.clim.2025.110557","url":null,"abstract":"<div><div>Therapeutical blockade of programmed cell death protein 1 (PD-1) axis may enhance anti-tumor immunity and especially natural killer (NK) cells activity. In 32 BRAF wild type (wt) metastatic melanoma (MM) patients before and after every 12 weeks of therapy with PD-1 inhibitor, Pembrolizumab, we analyzed the percentage of T cell subsets, NK cells and CD14<sup>+</sup>HLA-DR<sup>−</sup> monocytes, the expression of CD107a degranulation marker, activating NKG2D, NKp46, DNAM-1 and inhibitory CD158a receptors on NK cells by Flow cytometry, until one year or disease progression (DP). The patients with disease control (non-DP patients) had significant increase in lymphocyte count, percentage of NK cells, increased expression of CD107a, NKG2D, NKp46, but decreased CD158a on NK cells during Pembrolizumab therapy compared to pretherapy values. Patients with DP had increased neutrophil number, increased percentage of immunosuppressive CD14<sup>+</sup>HLA-DR<sup>−</sup> monocytes, as well as increased CD158a expression on NK cells. In MM patients with disease control, contrary to DP patients blocking of PD-1 inhibitory molecule may increase NK cell cytotoxicity through enhancement of NK cell degranulation and activating receptor expression. Therefore, our findings show that NK cells and their receptors in MM patients may be potential biomarkers of response to Pembrolizumab.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110557"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-11DOI: 10.1016/j.clim.2025.110564
Johanna Bodin , Anja Bråthen Kristoffersen , Tove Karin Herstad , Gro Tunheim , Sabin Bhandari , Anna Hayman Robertson , Ratnadeep Mukherjee , Unni Cecilie Nygaard , Fredrik Oftung , Lisbeth M. Næss
While severe COVID-19 is well-characterized, immune profiles of non-hospitalized, non-vaccinated individuals are less investigated. High-dimensional single-cell profiling and multiplex serum marker analysis characterized immune profiles according to outcome during acute infection and six months later. Lower IL-1RA and HGF levels, higher CD57+TIGIT+NKT, CD57+GrB+NKT, CD16+TIGIT+NK and CD4+CD57+GrB+ effector T-cell levels characterized asymptomatic infection. PMA + ionomycin induced higher frequencies of polyfunctional CD4+ and CD8+ effector T-cells in asymptomatic compared to moderate disease. Absence of multiple long-term symptoms was associated with higher CD16+TIGIT+NK-cell frequency, lower HGF levels and persisting high memory B and regulatory NK subpopulation levels. Higher frequency of CD16+TIGIT+ NK cells was in common for non-infected, asymptomatic, and individuals without multiple long-term symptoms. Compared to infected individuals, non-infected cases showed higher pre-existing T-cell responses to hCoV and SARS-CoV-2 peptides. This study contributes to increased understanding of protective immune responses in non-hospitalized COVID-19 cases, emphasizing the role of defined NK and T-cell subpopulations.
{"title":"High-dimensional immune profiling identifies circulating NK and T cell subpopulations associated with asymptomatic COVID-19 and absence of multiple long-term symptoms","authors":"Johanna Bodin , Anja Bråthen Kristoffersen , Tove Karin Herstad , Gro Tunheim , Sabin Bhandari , Anna Hayman Robertson , Ratnadeep Mukherjee , Unni Cecilie Nygaard , Fredrik Oftung , Lisbeth M. Næss","doi":"10.1016/j.clim.2025.110564","DOIUrl":"10.1016/j.clim.2025.110564","url":null,"abstract":"<div><div>While severe COVID-19 is well-characterized, immune profiles of non-hospitalized, non-vaccinated individuals are less investigated. High-dimensional single-cell profiling and multiplex serum marker analysis characterized immune profiles according to outcome during acute infection and six months later. Lower IL-1RA and HGF levels, higher CD57<sup>+</sup>TIGIT<sup>+</sup>NKT, CD57<sup>+</sup>GrB<sup>+</sup>NKT, CD16<sup>+</sup>TIGIT<sup>+</sup>NK and CD4<sup>+</sup>CD57<sup>+</sup>GrB<sup>+</sup> effector T-cell levels characterized asymptomatic infection. PMA + ionomycin induced higher frequencies of polyfunctional CD4<sup>+</sup> and CD8<sup>+</sup> effector T-cells in asymptomatic compared to moderate disease. Absence of multiple long-term symptoms was associated with higher CD16<sup>+</sup>TIGIT<sup>+</sup>NK-cell frequency, lower HGF levels and persisting high memory B and regulatory NK subpopulation levels. Higher frequency of CD16<sup>+</sup>TIGIT<sup>+</sup> NK cells was in common for non-infected, asymptomatic, and individuals without multiple long-term symptoms. Compared to infected individuals, non-infected cases showed higher pre-existing T-cell responses to hCoV and SARS-CoV-2 peptides. This study contributes to increased understanding of protective immune responses in non-hospitalized COVID-19 cases, emphasizing the role of defined NK and T-cell subpopulations.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110564"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-06-28DOI: 10.1016/j.clim.2025.110548
Jayhyun Kim , Jung Gon Kim , Yingjin Li , Sungyong You , Naeun Lee , Wan-Uk Kim
Lymphocyte-specific protein-1 (LSP1) is known to negatively regulate T cell migration in autoimmune diseases. However, its role in the development of T cell-dependent Sjögren's syndrome remains unknown. In this study, we found that LSP1 expression was decreased in T cells in salivary glands (SGs) of mice with experimental Sjögren's syndrome, accompanied by enhanced infiltration of leukocytes into SGs. Moreover, Lsp1−/− mice had higher frequency of IL-17A-expressing T cells in cervical lymph nodes as well as increased severity in SGs than WT mice. Concurrently, LSP1 expression was reduced in human T cells of primary Sjögren's syndrome (pSS) patient. Particularly, pSS patients showed an increased Th17 cells, which inversely correlated with LSP1 expression. Taken together, these findings suggest that LSP1 deficiency promote Th17 cell development and exacerbation of pSS. LSP1 might be a potential therapeutic target to regulate Th17 response and to treat autoimmune diseases like pSS.
{"title":"LSP1 deficiency increases IL-17-expressing T cells and accelerates primary Sjögren's syndrome","authors":"Jayhyun Kim , Jung Gon Kim , Yingjin Li , Sungyong You , Naeun Lee , Wan-Uk Kim","doi":"10.1016/j.clim.2025.110548","DOIUrl":"10.1016/j.clim.2025.110548","url":null,"abstract":"<div><div>Lymphocyte-specific protein-1 (LSP1) is known to negatively regulate T cell migration in autoimmune diseases. However, its role in the development of T cell-dependent Sjögren's syndrome remains unknown. In this study, we found that LSP1 expression was decreased in T cells in salivary glands (SGs) of mice with experimental Sjögren's syndrome, accompanied by enhanced infiltration of leukocytes into SGs. Moreover, <em>Lsp1</em><sup><em>−/−</em></sup> mice had higher frequency of IL-17A-expressing T cells in cervical lymph nodes as well as increased severity in SGs than WT mice. Concurrently, LSP1 expression was reduced in human T cells of primary Sjögren's syndrome (pSS) patient. Particularly, pSS patients showed an increased Th17 cells, which inversely correlated with LSP1 expression. Taken together, these findings suggest that LSP1 deficiency promote Th17 cell development and exacerbation of pSS. LSP1 might be a potential therapeutic target to regulate Th17 response and to treat autoimmune diseases like pSS.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110548"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-10DOI: 10.1016/j.clim.2025.110561
Weicheng Shen , Shengyan Cui , Yanqi Xia , Luo Duan , Yunpeng Dou , Han Zhao , Leixin Liu , Wei Wang , Ye Cui , Yan Chen , Jie Liu , Zhe Lv , Chris J. Corrigan , Huihui Yuan , Ying Sun
B-1 cells are derived from a subpopulation of B lymphocytes which have a specific developmental process, unique phenotype and location, and distinct functions in comparison with conventional B-2 cells. The origin of B-1 cells is not completely clear, with two existing hypotheses concerning their lineage and differentiation pathways. B-1 cells are located principally in the peritoneal and pleural cavities, but are also distributed in secondary lymphoid tissues, at mucosal sites and in the blood and bone marrow. B-1 cells regulate immune responses and maintain homeostasis by secretion of natural antibodies (nAbs), and participate in the adaptive immune response through phagocytosis and presentation of antigens to T cells. B-1 cells are associated with many diseases including autoimmune, infectious and inflammatory diseases. This review focuses on the origin and biological functions of B-1 cells as well as their involvement in human disease, and discusses advances in the understanding of the heterogeneity of B-1 cells under specific pathophysiological features, as partly clarified by single-cell sequencing analysis.
{"title":"Origin, functions, heterogeneity and associated diseases of B-1 cells","authors":"Weicheng Shen , Shengyan Cui , Yanqi Xia , Luo Duan , Yunpeng Dou , Han Zhao , Leixin Liu , Wei Wang , Ye Cui , Yan Chen , Jie Liu , Zhe Lv , Chris J. Corrigan , Huihui Yuan , Ying Sun","doi":"10.1016/j.clim.2025.110561","DOIUrl":"10.1016/j.clim.2025.110561","url":null,"abstract":"<div><div>B-1 cells are derived from a subpopulation of B lymphocytes which have a specific developmental process, unique phenotype and location, and distinct functions in comparison with conventional B-2 cells. The origin of B-1 cells is not completely clear, with two existing hypotheses concerning their lineage and differentiation pathways. B-1 cells are located principally in the peritoneal and pleural cavities, but are also distributed in secondary lymphoid tissues, at mucosal sites and in the blood and bone marrow. B-1 cells regulate immune responses and maintain homeostasis by secretion of natural antibodies (nAbs), and participate in the adaptive immune response through phagocytosis and presentation of antigens to T cells. B-1 cells are associated with many diseases including autoimmune, infectious and inflammatory diseases. This review focuses on the origin and biological functions of B-1 cells as well as their involvement in human disease, and discusses advances in the understanding of the heterogeneity of B-1 cells under specific pathophysiological features, as partly clarified by single-cell sequencing analysis.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110561"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ferroptosis is an iron-dependent cell death characterized by elevated levels of reactive oxygen species (ROS) and the peroxidation of membrane lipids, leading to cellular destruction. This phenomenon results from a disruption in the balance between oxidative and antioxidative processes, with oxidation involving iron and lipid metabolism, and antioxidation primarily relying on GPX4. Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell growth, accounting for 1.3 % of all malignancies. Despite advancements in treatment, MM still has a poor prognosis. Research indicates that malignant MM cells are susceptible to ferroptosis, suggesting that this process may serve as a novel therapeutic strategy to enhance the efficacy of treatment for MM. This review explores current insights into the cellular mechanisms of ferroptosis and its role in eliminating multiple myeloma cells, as well as its effectiveness alongside conventional drugs like Bortezomib.
{"title":"Iron-dependent cell death: Unlocking Ferroptosis as a key to multiple myeloma therapy","authors":"Fatemeh Karimian , Melika Khademi , Amirsalar Nikkhah Bahrami , Maryam Nabigol , Fatemeh Mikanik , Mehdi Bakhtiyaridovvombaygi , Nader Vazifeh Shiran","doi":"10.1016/j.clim.2025.110570","DOIUrl":"10.1016/j.clim.2025.110570","url":null,"abstract":"<div><div>Ferroptosis is an iron-dependent cell death characterized by elevated levels of reactive oxygen species (ROS) and the peroxidation of membrane lipids, leading to cellular destruction. This phenomenon results from a disruption in the balance between oxidative and antioxidative processes, with oxidation involving iron and lipid metabolism, and antioxidation primarily relying on GPX4. Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell growth, accounting for 1.3 % of all malignancies. Despite advancements in treatment, MM still has a poor prognosis. Research indicates that malignant MM cells are susceptible to ferroptosis, suggesting that this process may serve as a novel therapeutic strategy to enhance the efficacy of treatment for MM. This review explores current insights into the cellular mechanisms of ferroptosis and its role in eliminating multiple myeloma cells, as well as its effectiveness alongside conventional drugs like Bortezomib.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110570"},"PeriodicalIF":3.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-26DOI: 10.1016/j.clim.2025.110574
Guhan Luo , Rong Ni , Xuanwei Huang , Yuanhui Li , Dingcun Luo
The SLAM family receptors are immunoglobulin superfamily receptors integral to immune cell communication and regulation. This review consolidates current knowledge on the structures and functions of SLAM family receptors members (SLAMF1–SLAMF9), emphasizing their roles within the tumor microenvironment. Notably, SLAMF7 has been extensively studied in multiple myeloma, serving as both a diagnostic marker and therapeutic target. Other SLAM family receptors are implicated in tumor immune evasion, drug resistance, and T-cell exhaustion. Emerging therapies, including monoclonal antibodies and combinations with immune checkpoint inhibitors, are evaluated. Despite promising findings, challenges such as functional redundancy and an incomplete understanding of the roles of SLAM family receptors across different cancer types persist. Ongoing research into their molecular mechanisms and clinical applications is essential for advancing effective cancer immunotherapies.
{"title":"The role of signaling lymphocytic activation molecule (SLAM) family receptors in health and disease progression: Focusing on cancer and therapy","authors":"Guhan Luo , Rong Ni , Xuanwei Huang , Yuanhui Li , Dingcun Luo","doi":"10.1016/j.clim.2025.110574","DOIUrl":"10.1016/j.clim.2025.110574","url":null,"abstract":"<div><div>The SLAM family receptors are immunoglobulin superfamily receptors integral to immune cell communication and regulation. This review consolidates current knowledge on the structures and functions of SLAM family receptors members (SLAMF1–SLAMF9), emphasizing their roles within the tumor microenvironment. Notably, SLAMF7 has been extensively studied in multiple myeloma, serving as both a diagnostic marker and therapeutic target. Other SLAM family receptors are implicated in tumor immune evasion, drug resistance, and T-cell exhaustion. Emerging therapies, including monoclonal antibodies and combinations with immune checkpoint inhibitors, are evaluated. Despite promising findings, challenges such as functional redundancy and an incomplete understanding of the roles of SLAM family receptors across different cancer types persist. Ongoing research into their molecular mechanisms and clinical applications is essential for advancing effective cancer immunotherapies.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110574"},"PeriodicalIF":3.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-07-06DOI: 10.1016/j.clim.2025.110559
Manqi Tang , Weicheng Shen , Yanying Liu
Immunoglobulin G4-Related Disease (IgG4-RD) is a recently characterized systemic autoimmune disorder marked by multiorgan inflammation and progressive fibrosis. It can affect nearly any organ and may lead to serious clinical consequences. Despite recent progress in developing animal models, therapeutic options for IgG4-RD remain limited, and the pathogenic mechanisms underlying immune dysregulation and fibrosis are still not fully understood. To support mechanistic and therapeutic research, both humanized and non-humanized animal models have been established in recent years. However, the unique biological features of the IgG4 molecule, together with genetic differences between humans and mice, present significant challenges to conventional mouse models. Although several models replicate certain features of IgG4-RD, none fully recapitulate the pathological hallmarks observed in patients. This review critically examines the strengths and limitations of current experimental models and outlines future directions for improving IgG4-RD model systems to better reflect human disease pathogenesis.
{"title":"Animal models of IgG4-related disease","authors":"Manqi Tang , Weicheng Shen , Yanying Liu","doi":"10.1016/j.clim.2025.110559","DOIUrl":"10.1016/j.clim.2025.110559","url":null,"abstract":"<div><div>Immunoglobulin G4-Related Disease (IgG4-RD) is a recently characterized systemic autoimmune disorder marked by multiorgan inflammation and progressive fibrosis. It can affect nearly any organ and may lead to serious clinical consequences. Despite recent progress in developing animal models, therapeutic options for IgG4-RD remain limited, and the pathogenic mechanisms underlying immune dysregulation and fibrosis are still not fully understood. To support mechanistic and therapeutic research, both humanized and non-humanized animal models have been established in recent years. However, the unique biological features of the IgG4 molecule, together with genetic differences between humans and mice, present significant challenges to conventional mouse models. Although several models replicate certain features of IgG4-RD, none fully recapitulate the pathological hallmarks observed in patients. This review critically examines the strengths and limitations of current experimental models and outlines future directions for improving IgG4-RD model systems to better reflect human disease pathogenesis.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110559"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号